Area of research
Physiology · Immunology
Research interest
Research interests include Medicine, Asthma, Sputum, Immunology, Internal medicine, and Biomarker.
Predictors of Response to Biologics for Severe Asthma: A Systematic Review and Meta‐Analysis
Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study
Endotypes of severe neutrophilic and eosinophilic asthma from multi‐omics integration of U‐BIOPRED sputum samples
Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma
Discovery and Validation of a Volatile Signature of Eosinophilic Airway Inflammation in Asthma
Promoting Prevention and Targeting Remission of Asthma
Radiomultiomics: quantitative CT clusters of severe asthma associated with multiomics
Comparison of Asthma Phenotypes in Severe Asthma Cohorts (SARP, U-BIOPRED, ProAR and COREA) From 4 Continents
<i>Haemophilus influenzae</i> and <i>Moraxella catarrhalis</i> in sputum of severe asthma with inflammasome and neutrophil activation
Stratification of asthma by lipidomic profiling of induced sputum supernatant
Proteomic signatures of eosinophilic and neutrophilic asthma from serum and sputum
Oropharyngeal Microbiota Clusters in Children with Asthma or Wheeze Associate with Allergy, Blood Transcriptomic Immune Pathways, and Exacerbation Risk
The role of inflammation in anxiety and depression in the European U-BIOPRED asthma cohorts
Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study
Clinical and transcriptomic features of persistent exacerbation‐prone severe asthma in U‐BIOPRED cohort
Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study
Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study
Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation
A multi-omics approach to delineate sputum microbiome-associated asthma inflammatory phenotypes
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial
Sputum microbiome profiles identify severe asthma phenotypes of relative stability at 12 to 18 months
Urinary Leukotriene E4 and Prostaglandin D2 Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational Study
eNose breath prints as a surrogate biomarker for classifying patients with asthma by atopy
Type 2‐low asthma phenotypes by integration of sputum transcriptomics and serum proteomics
Instability of sputum molecular phenotypes in U-BIOPRED severe asthma
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline
Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study
IL-17–high asthma with features of a psoriasis immunophenotype
ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions